Ultragenyx Pharma Reports Narrowing Losses, Announces 10% Workforce Reduction

Ultragenyx Pharmaceuticals (NASDAQ: UGRX) reported a narrowing loss in the fourth quarter of 2025, with net loss shrinking to $127 million from $154 million in the prior-year period, according to a Feb 12 filing. The company announced plans to reduce its workforce by 10%, or approximately 200 employees, effective in 2026 to align with its evolving business strategy and optimize expenses. The reduction follows continued pressure from high development costs and limited commercial traction for its lead product, Zolgensma, a gene therapy for spinal muscular atrophy. Revenue for 2025 was $168 million, down from $208 million in 2024, reflecting the company's shift toward more efficient operations.